St. Vincent & Grenadines Business Hub
SEE OTHER BRANDS

Reporting on business and economy news in Saint Vincent and the Grenadines

Spectrum Pharmaceuticals (SPPI) Lawsuit Re-Opens Lead Plaintiff Process: New Lead Plaintiff Needed After Disqualification

SPPI Investors with Losses Encouraged to Contact Hagens Berman

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action, offering a new opportunity for investors to represent the class. The action follows the court's decision on August 4, 2025, to disqualify the previously appointed lead plaintiff. The new deadline to apply is September 24, 2025.

Hagens Berman urges Spectrum investors who suffered substantial losses to submit your losses now.

Class Period: Mar. 17, 2022 – Sept. 22, 2022
Lead Plaintiff Deadline: Sept. 24, 2025
Visit: www.hbsslaw.com/investor-fraud/sppi  
Contact the Firm Now: SPPI@hbsslaw.com
                                       844-916-0895

The federal class action, Christiansen v. Spectrum Pharmaceuticals, Inc., et al., has been ongoing in the Southern District of New York since late 2022. It alleges that Spectrum misled investors about its drug, poziotinib, a candidate for treating non-small cell lung cancer. The complaint claims the company made false statements about the drug's safety and efficacy, and failed to disclose that it had not enrolled any patients in a required Phase 3 clinical trial. These alleged omissions came to light in September 2022 when an FDA Oncologic Drugs Advisory Committee briefing document revealed critical negative data, causing Spectrum’s stock to crash.

Hagens Berman Urges Investors to Act

National shareholders’ rights firm Hagens Berman is actively investigating the claims and encouraging investors who suffered significant losses to consider becoming the new lead plaintiff. As a lead plaintiff, you would play a vital role in overseeing the litigation and protecting the interests of all investors in the class

If you’d like more information and answers to frequently asked questions about the Spectrum Pharmaceuticals case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Spectrum should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email SPPI@hbsslaw.com.

About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw

Contact:
Reed Kathrein, 844-916-0895


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions